$100 Mil. Pharmaceutical Media Business in Play

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

Prescription-drug marketer AstraZeneca Pharmaceuticals is in the early stages of planning a media buying consolidation, sources said. The combined account will be worth an estimated $100 million in billings.

The Wilmington, Del.-based client has quietly begun contacting its roster shops about a review and is developing a request for proposals to send to contenders, sources said.

It is not known whether outside agencies will be invited to participate in the consolidation search.

An AstraZeneca representative declined to comment on the report of a media consolidation review.

The bulk of the business will come from Nexium, the successor drug to the company’s successful heartburn product, Priolsec, which is the world’s best-selling prescription drug.







AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Spring Special

Save 30% Off an ADWEEK Subscription Today!

View Your Options

Already a member? Sign in